ID   M229DDRpoly-PLXAZD
AC   CVCL_IM72
DR   cancercelllines; CVCL_IM72
DR   GEO; GSM1588916
DR   Wikidata; Q54903542
RX   PubMed=26359985;
CC   Selected for resistance to: ChEBI; CHEBI_90227; Selumetinib (AZD6244).
CC   Selected for resistance to: ChEBI; CHEBI_63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D748 ! M229
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 19-12-24; Version: 11
//
RX   PubMed=26359985; DOI=10.1016/j.cell.2015.07.061; PMCID=PMC4821508;
RA   Hugo W., Shi H.-B., Sun L., Piva M., Song C.-Y., Kong X.-J., Moriceau G.,
RA   Hong A., Dahlman K.B., Johnson D.B., Sosman J.A., Ribas A., Lo R.S.;
RT   "Non-genomic and immune evolution of melanoma acquiring MAPKi
RT   resistance.";
RL   Cell 162:1271-1285(2015).
//